Cas9 Stable Cell Line - BXPC-3

TGF-β signaling is essential in pancreatic ductal adenocarcinoma (PDAC) development, altered in all PDAC cases as one of four major pathways. Researchers demonstrate the crucial role of SMAD2/3 in pancreatic ductal adenocarcinoma (PDAC) progression, particularly in SMAD4-null contexts. By investigating TGF-β signaling in PDAC cells lacking SMAD4, they reveal SMAD2/3's oncogenic effects, influencing collective migration through FAK and Rho/Rac signaling pathways. RNA-sequencing analyses unveil a TGF-β gene signature linked to aggressive behavior, facilitated by SMAD2/3 activation. Additionally, clinical data suggests that SMAD4-negative tumors with elevated phospho-SMAD2 levels exhibit increased aggressiveness and poorer prognosis. These findings underscore the complex interplay between TGF-β signaling components in PDAC, highlighting SMAD2/3 as potential therapeutic targets.

Figure 1. A double SMAD2/SMAD3 knockout BxPC-3 (SMAD4-negative) pancreatic cancer cell line was generated. SMAD protein expression and localization in response to TGF-β treatment were assessed. Altered SMAD2/3 levels and distribution were observed in knockout cells compared to controls, providing insights into TGF-β signaling in pancreatic cancer progression. (Bertrand-Chapel A, et al., 2022)

Utilizing Creative Biogene's Cas9 Stable Cell Line-BXPC-3 streamlines the process of SMAD2/SMAD3 gene knockout experiments. This stable cell line is directly amenable to CRISPR/Cas9 gene editing technology, facilitating the rapid generation of SMAD2/SMAD3 knockout cell lines, thereby saving time and resources. Such cell lines can be instrumental in investigating the TGF-β signaling pathway and its implications in pancreatic cancer progression, enhancing the convenience and efficiency of related disease research endeavors.